TG4010 clinical trials
Also written TG4010.
How each study uses TG4010 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2000 (1)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2005 | 1 |
| 2012 | 1 |
| 2016 | 1 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 2
Transgene (4) · Megan Daly, MD (1) · Jonsson Comprehensive Cancer Center (1)
Studies
Open first, then newest update. How each study uses TG4010 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- TG4010 and Nivolumab in Patients With Lung CancerCompletedPhase 2Megan Daly, MDNCT02823990Written as TG4010How we know
- A Study Evaluating the Efficacy and the Safety of First-line Chemotherapy Combined With the Therapeutic Vaccine Named TG4010 and Nivolumab in Patients With Advanced Non-squamous Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 2TransgeneNCT03353675Written as TG4010How we know
- Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung CancerTerminatedPhase 2/3TransgeneNCT01383148Written as TG4010How we know
- Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung CancerCompletedPhase 2/3TransgeneNCT00415818Written as MVA-MUC1-IL2How we know
- Vaccine Therapy in Treating Patients With Advanced CancerCompletedPhase 1Jonsson Comprehensive Cancer CenterNCT00004881Written as MVA-MUC1-IL2 vaccineHow we know
- Vaccine Study of MVA-MUC1-IL2 in Patients With Prostate CancerTerminatedPhase 2TransgeneNCT00040170Written as MVA-MUC1-IL2How we know